Loading...

FITC anti-mouse I-A/I-E Antibody

Pricing & Availability
Clone
M5/114.15.2 (See other available formats)
Regulatory Status
RUO
Other Names
MHC class II
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
m5/114.15.2 FITC
C57BL/6 mouse splenocytes were stained with anti-mouse I-A/I-E (clone M5/114.15.2) FITC (solid line) or rat IgG2b, κ FITC isotype control (dashed line).
  • m5/114.15.2 FITC
    C57BL/6 mouse splenocytes were stained with anti-mouse I-A/I-E (clone M5/114.15.2) FITC (solid line) or rat IgG2b, κ FITC isotype control (dashed line).
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
107605 50 µg 57€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
107606 500 µg 176€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

These class II molecules are expressed on antigen presenting cells (including B cells) and a subset of T cells from H-2b,d,q,r bearing mice and are involved in antigen presentation to T cells expressing CD3/TCR and CD4 proteins.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Activated C57BL/6 mouse spleen cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

The M5/114.15.2 antibody reacts with a polymorphic determinant shared by the I-Ab, I-Ad, I-Aq, I-Ed, and I-Ek MHC class II alloantigens from mice carrying H-2p,r,q,b,d,u haplotypes. Clone M5/114.15.2 however does not react wtih I-Af, I-Ak, or I-As MHC class II alloantigens.1

Additional reported applications (for the relevant formats) include: immunoprecipitation1, immunohistochemistry of frozen sections2,3,6, in vitro and in vivo blocking of antigen presentation or ligand binding4-7, and spatial biology (IBEX)17,18. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 107655 & 107656).

Application References

(PubMed link indicates BioLegend citation)
  1. Bhattacharya A, et al. 1981. J. Immunol. 127:2488. (IP)
  2. Viville S, et al. 1993. Cell 72:635. (IHC)
  3. Nelson AJ, et al. 1993. J. Immunol. 151:2453. (IHC)
  4. Shi Y, et al. 1998. J. Exp. Med. 187:367. (Block)
  5. Yamashita I, et al. 1993. Int. Immunol. 5:1139.
  6. Guo M, et al. 1995. Zygote 3:65. (IHC)
  7. Kim A, et al. 2004. Exp. Mol. Med. 36:428. (Block)
  8. Luckashenak NA, et al. 2006. J. Immunol. 177:5177.
  9. Venanzi ES, et al. 2007. J. Immunol. 179:5693.
  10. Christensen SR, et al. 2006. Immunity 25:417. PubMed
  11. Matte-Martone C, et al. 2008. Blood 111:3884. PubMed
  12. De Pascalis R, et al. 2008. Infect. Immun. 76:4311. PubMed
  13. Kuns RD, et al. 2009. Blood 113:5999. PubMed
  14. Sabatino JJ, et al. 2011. J. Exp. Med. 208:81. PubMed
  15. Draber P, et al. 2011. Mol Cell Biol. 22:4550. PubMed
  16. Fu H, et al. 2014. Nat Commun. 5:3436. PubMed
  17. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  18. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Nguyen T, et al. 2021. STAR Protoc. 2:101004. PubMed
  2. Wang S, et al. 2022. Sci Adv. 8:eabn3883. PubMed
  3. Gargaro M, et al. 2022. Immunity. 55:1032. PubMed
  4. Mugarza E, et al. 2022. Sci Adv. 8:eabm8780. PubMed
  5. Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed
  6. Montilla A, et al. 2023. Cell Death Dis. 14:16. PubMed
  7. Tanaka T, et al. 2023. Nat Immunol. 24:439. PubMed
  8. Drummer C, et al. 2023. Front Immunol. 14:1113883. PubMed
  9. Yang Z, et al. 2022. J Nucl Med. 63:1708. PubMed
  10. Lopez R, et al. 2022. Nat Biotechnol. 40:1360. PubMed
  11. Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed
  12. Koyama M, et al. 2015. J Exp Med. 212: 1303 - 1321. PubMed
  13. Sheng YH, et al. 2022. Cell Mol Gastroenterol Hepatol. 14:789. PubMed
  14. Qiu Z, et al. 2022. J Exp Med. 219:. PubMed
  15. Sauter M, et al. 2022. STAR Protoc. 3:101664. PubMed
  16. Pagni RL, et al. 2022. Front Immunol. 13:1005937. PubMed
  17. Chen X, et al. 2023. Adv Mater. 35:e2210440. PubMed
  18. Zhao Q, et al. 2023. Signal Transduct Target Ther. 8:40. PubMed
  19. Do-Thi VA, et al. 2023. Cancer Res Commun. 3:80. PubMed
  20. Guo Z, et al. 2023. Int J Mol Sci. 24:. PubMed
  21. Yao H, et al. 2023. Front Immunol. 14:1147674. PubMed
  22. Shen Z, et al. 2023. iScience. 26:106572. PubMed
  23. He Y, et al. 2023. Biomolecules. 13:. PubMed
  24. Hsieh MS, et al. 2023. NPJ Vaccines. 8:82. PubMed
  25. Yao RQ, et al. 2023. Mil Med Res. 10:27. PubMed
  26. Sim SL, et al. 2022. Front Endocrinol (Lausanne). 13:957833. PubMed
  27. Tarban N, et al. 2022. Cells. 11:. PubMed
  28. Jong RM, et al. 2022. J Immunol. 208:407. PubMed
  29. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  30. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  31. Pierini S, et al. 2021. J Immunother Cancer. 9:. PubMed
  32. Du J, et al. 2020. Developmental Cell. 55(6):737-753.e7. PubMed
  33. Orillion A, et al. 2018. Clin Cancer Res. 24:6383. PubMed
  34. Mulder R, et al. 2017. Front Immunol. 1.464583333. PubMed
  35. Hickey A, et al. 2021. Front Microbiol. 12:653587. PubMed
  36. Piepke M, et al. 2021. J Neuroinflammation. 18:265. PubMed
  37. Sauter M, et al. 2022. iScience. 25:103677. PubMed
  38. Nakamura M, et al. 2015. J Immunol. 194:243. PubMed
  39. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  40. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  41. Matsumura F, et al. 2021. J Immunol. 207:938. PubMed
  42. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
  43. Dutta S, et al. 2012. Eukaryot Cell. 0.756944444. PubMed
  44. He Y, et al. 2020. Sci Adv. 6:eaba7589. PubMed
  45. Hays C, et al. 2020. eLife. 8:e48772.. PubMed
  46. Sultan H, et al. 2018. Cancer Immunol Res. 6:617. PubMed
  47. Zhao J, et al. 2019. Nat Commun. 10:899. PubMed
  48. Enriquez AB, et al. 2022. iScience. 25:104305. PubMed
  49. Renga G, et al. 2020. Life Sci Alliance. 3:. PubMed
  50. Zhu B, et al. 2021. Immunity. 54(6):1200-1218.e9. PubMed
  51. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  52. Ayasoufi K, et al. 2020. Brain. 3629:143. PubMed
  53. Wang H et al. 2017. Developmental cell. 40(6):566-582 . PubMed
  54. Kimura A, et al. 2018. J Exp Med. 215:2197. PubMed
  55. Wang L, et al. 2021. Cancer Immunol Res. 9:348. PubMed
  56. Enriquez AB, et al. 2022. iScience. 25:104305. PubMed
  57. Mainz RE, et al. 2022. Cells. 11:. PubMed
  58. Zhao F, et al. 2022. Front Immunol. 13:873720. PubMed
  59. Qu J, et al. 2018. J Immunol Res. 2018:7519856. PubMed
  60. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  61. Zhang P, et al. 2022. BMC Med. 20:435. PubMed
  62. Kang SJ, et al. 2022. Food Sci Anim Resour. 42:903. PubMed
  63. Carozza JA, et al. 2020. Nat Cancer. 184:1. PubMed
  64. Wang Y, et al. 2021. Sci Rep. 1.429861111. PubMed
  65. Reynolds A, et al. 2015. J Immunol. 194:231. PubMed
  66. Morris E, et al. 2005. J Clin Invest. 115:3093. PubMed
  67. Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed
  68. Tsukasaki M, et al. 2020. Cell Reports. 32(10):108124. PubMed
  69. Hernández–Santos N, et al. 2018. Cell Host Microbe. 1.313194444. PubMed
  70. Alikhanyan K, et al. 2021. Cancers (Basel). 13:. PubMed
  71. Zou J, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:983. PubMed
  72. Miki Y, et al. 2016. J Biol Chem. 291: 15588 - 15601. PubMed
  73. Kaplan D, et al. 2007. J Exp Med. 204:2545. PubMed
  74. Pradhan K, et al. 2021. Front Immunol. 12:778830. PubMed
  75. Dobosz E, et al. 2021. Dis Model Mech. :14. PubMed
  76. Bayik D, et al. 2020. Cancer Discov. 1.256944444. PubMed
  77. Koma T, et al. 2014. J Virol. 88:7178. PubMed
  78. Vorselen D, et al. 2021. Elife. 10:. PubMed
  79. White C, et al. 2015. J Immunol. 194:697. PubMed
  80. Engler AE, et al. 2020. Cell Reports. 33(13):108553. PubMed
  81. Kim SH, et al. 2021. Cell Reports. 35(2):108995. PubMed
  82. Donaldson B, et al. 2017. J Immunother Cancer. 10.1186/s40425-017-0270-1. PubMed
  83. Zhang J, et al. 2018. Sci Rep. 8:2373. PubMed
  84. Hakim R, et al. 2019. Stem Cell Res Ther. 10:115. PubMed
  85. Kramer K, et al. 2017. ACS Omega. 0.240972222. PubMed
  86. Otvos B, et al. 2021. Clin Cancer Res. 27:2038. PubMed
  87. Maulloo CD, et al. 2021. Front Immunol. 12:714842. PubMed
  88. Koikawa K, et al. 2021. Cell. 184:4753. PubMed
  89. Dewi IMW, et al. 2021. Cell Reports Medicine. 2(5):100289. PubMed
  90. Maisel D, et al. 2016. PLoS One. 11: 0159716. PubMed
  91. Steinbach K, et al. 2013. J Immunol. 191:4531. PubMed
  92. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  93. Guo S, et al. 2021. Sci Rep. 11:23745. PubMed
  94. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
  95. Van Dis E, et al. 2018. Cell Rep. 23:1435. PubMed
  96. Ghorbani S, et al. 2022. Nat Commun. 13:2445. PubMed
  97. Zhao L, et al. 2021. STAR Protocols. 2:100732. PubMed
  98. Kang J, Lee J, Chang J 2016. PLoS One. 11: 0157015. PubMed
  99. Banovic T, et al. 2009. J Immunol. 182:912. PubMed
  100. Zwick M, et al. 2019. Front Immunol. 10:222. PubMed
  101. Budai Z, et al. 2021. Cells. 10:. PubMed
  102. Luo M, et al. 2021. J Immunol. 207:1683. PubMed
  103. Hidaka T, et al. 2016. Nat Immunol. 18:64-73. PubMed
  104. Kelly SH, et al. 2021. Adv Healthc Mater. 10:e2001614. PubMed
  105. Bagati A, et al. 2020. Cancer Cell. 39(1):54-67.e9. PubMed
  106. Moufarrij S, et al. 2020. Sci Rep. 10:3470. PubMed
  107. Wu J, et al. 2019. J Immunol Res. 2019:1749803. PubMed
  108. Grube J, et al. 2022. Cell Death Dis. 13:704. PubMed
  109. Schulz A, et al. 2015. J Biol Chem. 211: 553 - 567. PubMed
  110. Kramer K, et al. 2017. Mol Ther. 25(1):62-70. PubMed
  111. Wijayadikusumah A, et al. 2017. Amino Acids. 10.1007/s00726-017-2466-6. PubMed
  112. Sivapatham S, et al. 2019. Front Immunol. 1.865277778. PubMed
  113. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  114. Xiao S, Manley N 2010. PLoS One. 5:e15396. PubMed
  115. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  116. Xiao Z, et al. 2022. Mater Today Bio. 15:100297. PubMed
  117. Nicholls J, et al. 2021. Front Cell Dev Biol. 9:737880. PubMed
  118. Chetty A, et al. 2021. Cell Host Microbe. 29:579. PubMed
  119. Aguilera TA, et al. 2020. Clin Cancer Res. 26:2972. PubMed
  120. Danne C et al. 2017. Cell host & microbe. 22(6):733-745 . PubMed
  121. Al-Zaeed N, et al. 2021. Cell Death Dis. 12:611. PubMed
  122. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  123. Stack G, et al. 2015. PLoS Pathog. 11:1004641. PubMed
  124. Harberts E, et al. 2015. J Immunol. 194:3127. PubMed
  125. Tran S, et al. 2020. Immunity. 53(3):627-640.e5. PubMed
  126. Arima Y et al. 2017. eLife. 6 pii: e25517. PubMed
  127. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  128. Krotova K, et al. 2019. Mol Ther Oncolytics. 15:166. PubMed
  129. Steinmann S, et al. 2020. Sci Rep. 1.160416667. PubMed
  130. Deets KA, et al. 2021. Elife. 10:. PubMed
  131. Spanier J, et al. 2016. Nat Commun. 7:11804. PubMed
  132. Dong S, et al. 2007. Int Immunopharmacol. 7:725. PubMed
  133. Park CJ, et al. 2020. Cell Reports. 31(2):107496.. PubMed
RRID
AB_313320 (BioLegend Cat. No. 107605)
AB_313320 (BioLegend Cat. No. 107606)

Antigen Details

Structure
MHC class II
Distribution

B cell and activated T cells, APCs of the H-2b,d,q,r bearing mice

Function
Antigen presentation
Ligand/Receptor
CD3/TCR, CD4
Cell Type
Antigen-presenting cells, B cells, Dendritic cells, T cells, Tregs
Biology Area
Immunology, Innate Immunity
Molecular Family
MHC Antigens
Antigen References

1. Watts C. 1997. Ann. Rev. Immunol. 15:821.
2. Pamer E, et al. 1998. Ann. Rev. Immunol. 16:323.

Gene ID
14961 View all products for this Gene ID 14969 View all products for this Gene ID
UniProt
View information about I-A/I-E on UniProt.org

Other Formats

View All I-A/I-E Reagents Request Custom Conjugation
Description Clone Applications
Biotin anti-mouse I-A/I-E M5/114.15.2 FC
FITC anti-mouse I-A/I-E M5/114.15.2 FC
PE anti-mouse I-A/I-E M5/114.15.2 FC
Purified anti-mouse I-A/I-E M5/114.15.2 FC,IHC-F,IP,Block
PE/Cyanine5 anti-mouse I-A/I-E M5/114.15.2 FC
APC anti-mouse I-A/I-E M5/114.15.2 FC
Alexa Fluor® 488 anti-mouse I-A/I-E M5/114.15.2 FC,3D IHC
Alexa Fluor® 647 anti-mouse I-A/I-E M5/114.15.2 FC
Pacific Blue™ anti-mouse I-A/I-E M5/114.15.2 FC
Alexa Fluor® 700 anti-mouse I-A/I-E M5/114.15.2 FC,SB
PerCP/Cyanine5.5 anti-mouse I-A/I-E M5/114.15.2 FC
PerCP anti-mouse I-A/I-E M5/114.15.2 FC
APC/Cyanine7 anti-mouse I-A/I-E M5/114.15.2 FC
PE/Cyanine7 anti-mouse I-A/I-E M5/114.15.2 FC
Brilliant Violet 421™ anti-mouse I-A/I-E M5/114.15.2 FC,IHC-F,SB
Brilliant Violet 510™ anti-mouse I-A/I-E M5/114.15.2 FC
Purified anti-mouse I-A/I-E (Maxpar® Ready) M5/114.15.2 FC,CyTOF®
Brilliant Violet 605™ anti-mouse I-A/I-E M5/114.15.2 FC
Brilliant Violet 650™ anti-mouse I-A/I-E M5/114.15.2 FC
Brilliant Violet 711™ anti-mouse I-A/I-E M5/114.15.2 FC
Brilliant Violet 785™ anti-mouse I-A/I-E M5/114.15.2 FC
PE/Dazzle™ 594 anti-mouse I-A/I-E M5/114.15.2 FC
Alexa Fluor® 594 anti-mouse I-A/I-E M5/114.15.2 IHC-F,3D IHC
APC/Fire™ 750 anti-mouse I-A/I-E M5/114.15.2 FC
TotalSeq™-A0117 anti-mouse I-A/I-E M5/114.15.2 PG
Ultra-LEAF™ Purified anti-mouse I-A/I-E M5/114.15.2 FC,IHC-F,IP,Block
TotalSeq™-B0117 anti-mouse I-A/I-E M5/114.15.2 PG
TotalSeq™-C0117 anti-mouse I-A/I-E M5/114.15.2 PG
Spark Blue™ 550 anti-mouse I-A/I-E M5/114.15.2 FC
PE/Fire™ 640 anti-mouse I-A/I-E M5/114.15.2 FC
Spark YG™ 581 anti-mouse I-A/I-E M5/114.15.2 FC
PE/Fire™ 810 anti-mouse I-A/I-E M5/114.15.2 FC
Spark UV™ 387 anti-mouse I-A/I-E M5/114.15.2 FC
Spark Violet™ 538 anti-mouse I-A/I-E M5/114.15.2 FC
PerCP/Fire™ 806 anti-mouse I-A/I-E M5/114.15.2 FC
Spark Red™ 718 anti-mouse I-A/I-E M5/114.15.2 FC
APC/Fire™ 810 anti-mouse I-A/I-E M5/114.15.2 FC
Spark PLUS UV395™ anti-mouse I-A/I-E M5/114.15.2 FC
Go To Top Version: 4    Revision Date: 10.30.2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account